Clinical outcomes and nephrotoxicity associated with vancomycin trough concentrations during treatment of deep-seated infections

被引:87
|
作者
Hermsen, Elizabeth D. [1 ,2 ,5 ]
Hanson, Monica [1 ]
Sankaranarayanan, Jayashri [2 ]
Stoner, Julie A. [3 ]
Florescu, Marius C. [4 ]
Rupp, Mark E. [5 ]
机构
[1] Univ Nebraska Med Ctr, Dept Pharmaceut & Nutr Care, Omaha, NE 68918 USA
[2] Univ Nebraska Med Ctr, Coll Pharm, Dept Pharm Practice, Omaha, NE 68918 USA
[3] Univ Oklahoma, Coll Publ Hlth, Hlth Sci Ctr, Dept Biostat & Epidemiol, Oklahoma City, OK USA
[4] Univ Nebraska Med Ctr, Coll Med, Nephrol Sect, Dept Internal Med, Omaha, NE 68918 USA
[5] Univ Nebraska Med Ctr, Coll Med, Infect Dis Sect, Dept Internal Med, Omaha, NE 68918 USA
关键词
outcome assessment; therapeutic drug monitoring; toxicity; vancomycin; STAPHYLOCOCCUS-AUREUS; EFFICACY;
D O I
10.1517/14740330903413514
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Objective: Higher vancomycin concentrations are thought necessary for treatment of deep-seated methicillin-resistant Staphylococcus aureus (MRSA) infection, yet this may result in greater risk of nephrotoxicity. We evaluated the relationship of serum vancomycin trough concentration with clinical outcomes and nephrotoxicity for patients with deep-seated MRSA infection. Methods: A retrospective cohort study evaluated adults with MRSA pneumonia, endocarditis or osteomyelitis who received vancomycin for 5 days from June 2005 to June 2007. Patients were stratified by mean vancomycin trough level [low (< 15 mg/l), high (>= 15 mg/l)]. Outcomes were clinical response, mortality, length of stay (LOS) and nephrotoxicity. Three definitions of nephrotoxicity were used: i) rise in serum creatinine (SCr) >= 0.5 mg/dl; ii) 50% increase in SCr; and iii) 25% decrease in estimated creatinine clearance. Results: Fifty-five patients experiencing MRSA pneumonia (n = 28), endocarditis (n = 9), osteomyelitis (n = 20) and multiple infections (n = 2) were stratified into low (n = 39) and high (n = 16) groups. High group patients were more likely to be septic (p = 0.01) and have a higher APACHE II score (p = 0.01). After adjustment for APACHE II score, clinical response rates among survivors did not differ significantly. Risk of death was not significantly different between the high (19%) and low (5%) group patients (p = 0.1). LOS did not differ significantly between groups (p = 0.7). Nephrotoxicity occurred in the low and high groups, respectively, for 10 and 31% (p = 0.04) with definition 1, 10 and 31% (p = 0.04) with definition 2, and 13 and 25% (p = 0.1) with definition 3. After adjustment for APACHE II score, odds of nephrotoxicity based on definitions 1 or 2 were increased among the high versus low groups (OR = 3.27, 95% Cl: 0.7 15.25, p = 0.1), although not statistically significant. Conclusions: Clinical outcomes did not differ significantly between high and low trough groups for deep-seated MRSA infections. Nephrotoxicity was consistently higher in the high trough group, regardless of the definition used.
引用
收藏
页码:9 / 14
页数:6
相关论文
共 50 条
  • [1] Vancomycin Trough Concentrations and Outcomes in Non-deep Seated Infections: A Retrospective Cohort Study
    Wan, M.
    Walker, S. A. N.
    Martin, E.
    Elligsen, M.
    Palmay, L.
    Leis, J. A.
    CANADIAN JOURNAL OF HOSPITAL PHARMACY, 2018, 71 (01): : 55 - 55
  • [2] The impact of vancomycin trough concentrations on outcomes in non-deep seated infections: a retrospective cohort study
    Michael Wan
    Sandra A. N. Walker
    Elaine Martin
    Marion Elligsen
    Lesley Palmay
    Jerome A. Leis
    BMC Pharmacology and Toxicology, 19
  • [3] The impact of vancomycin trough concentrations on outcomes in non-deep seated infections: a retrospective cohort study
    Wan, Michael
    Walker, Sandra A. N.
    Martin, Elaine
    Elligsen, Marion
    Palmay, Lesley
    Leis, Jerome A.
    BMC PHARMACOLOGY & TOXICOLOGY, 2018, 19
  • [4] The Thirty-Day Mortality Rate and Nephrotoxicity Associated With Trough Serum Vancomycin Concentrations During Treatment of Enterococcal Infections: A Propensity Score Matching Analysis
    Katip, Wasan
    Okonogi, Siriporn
    Oberdorfer, Peninnah
    FRONTIERS IN PHARMACOLOGY, 2022, 12
  • [5] POOR EFFICACY OF TEICOPLANIN IN TREATMENT OF DEEP-SEATED STAPHYLOCOCCAL INFECTIONS
    GALANAKIS, N
    GIAMARELLOU, H
    VLACHOGIANNIS, N
    DENDRINOS, C
    DAIKOS, GK
    EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 1988, 7 (02) : 130 - 134
  • [6] Treatment Outcomes with Cefazolin versus Oxacillin for Deep-Seated Methicillin-Susceptible Staphylococcus aureus Bloodstream Infections
    Rao, Sonia N.
    Rhodes, Nathaniel J.
    Lee, Benjamin J.
    Scheetz, Marc H.
    Hanson, Amy P.
    Segreti, John
    Crank, Christopher W.
    Wang, Sheila K.
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2015, 59 (09) : 5232 - 5238
  • [7] SURGICAL TREATMENT OF DEEP-SEATED TUMORS ASSOCIATED WITH BARRE-MASSON SYNDROME
    SELIVANOV, VP
    VOPROSY ONKOLOGII, 1977, 23 (12) : 82 - 84
  • [8] A Monocentric Retrospective Study of AUC/MIC Ratio of Vancomycin Associated with Clinical Outcomes and Nephrotoxicity in Patients with Enterococcal Infections
    Katip, Wasan
    Oberdorfer, Peninnah
    PHARMACEUTICS, 2021, 13 (09)
  • [9] Outcomes and Nephrotoxicity Associated with Vancomycin Treatment in Patients 80 Years and Older
    Wang, Yunchao
    Dai, Ning
    Wei, Wei
    Jiang, Chunyan
    CLINICAL INTERVENTIONS IN AGING, 2021, 16 : 1023 - 1035
  • [10] Diffusion changes in minimally invasive parafascicular approach for deep-seated tumours: impact on clinical outcomes
    Awan, Mariam
    Elshalakany, Aya
    Kalaitzoglou, Dimitrios
    Kalyal, Nida
    Sinha, Siddharth
    Perera, Andrea
    Wright, Oliver Wroe
    Gallagher, Mathew J.
    Richardson, Daniel
    Elhag, Ali
    Marchi, Francesco
    Abougamil, Ahmed
    Silva, Melissa
    Oviedova, Anna
    Patel, Sabina
    Mirallave-Pescador, Ana
    Diaz-Baamonde, Alba
    Bleil, Cristina
    Zebian, Bassel
    Gullan, Richard
    Ashkan, Keyoumars
    Vergani, Francesco
    Bhangoo, Ranjeev
    Lavrador, Jose Pedro
    NEUROSURGICAL REVIEW, 2025, 48 (01)